{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Hasan MN"],"funding":["NIDDK NIH HHS"],"pagination":["100340"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC9986646"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["64(3)"],"pubmed_abstract":["Therapeutic reduction of hydrophobic bile acids exposure is considered beneficial in cholestasis. The Cyp2c70 KO mice lack hydrophilic muricholic acids and have a human-like hydrophobic bile acid pool resulting in hepatobiliary injury. This study investigates if combining an apical sodium-dependent bile acid transporter inhibitor GSK2330672 (GSK) and fibroblast growth factor-15 (FGF15) overexpression, via simultaneous inhibition of bile acid synthesis and gut bile acid uptake, achieves enhanced therapeutic efficacy in alleviating hepatobiliary injury in Cyp2c70 KO mice. The effects of GSK, adeno-associated virus (AAV)-FGF15, and the combined treatment on bile acid metabolism and cholangiopathy were compared in Cyp2c70 KO mice. In female Cyp2c70 KO mice with more severe cholangiopathy than "],"journal":["Journal of lipid research"],"pubmed_title":["Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice."],"pmcid":["PMC9986646"],"funding_grant_id":["R01 DK117965","R01 DK131064"],"pubmed_authors":["Matye D","Chen J","Clayton YD","Li T","Luo W","Gu L","Du Y","Wang H","Hasan MN"],"additional_accession":[]},"is_claimable":false,"name":"Combining ASBT inhibitor and FGF15 treatments enhances therapeutic efficacy against cholangiopathy in female but not male Cyp2c70 KO mice.","description":"Therapeutic reduction of hydrophobic bile acids exposure is considered beneficial in cholestasis. The Cyp2c70 KO mice lack hydrophilic muricholic acids and have a human-like hydrophobic bile acid pool resulting in hepatobiliary injury. This study investigates if combining an apical sodium-dependent bile acid transporter inhibitor GSK2330672 (GSK) and fibroblast growth factor-15 (FGF15) overexpression, via simultaneous inhibition of bile acid synthesis and gut bile acid uptake, achieves enhanced therapeutic efficacy in alleviating hepatobiliary injury in Cyp2c70 KO mice. The effects of GSK, adeno-associated virus (AAV)-FGF15, and the combined treatment on bile acid metabolism and cholangiopathy were compared in Cyp2c70 KO mice. In female Cyp2c70 KO mice with more severe cholangiopathy than ","dates":{"release":"2023-01-01T00:00:00Z","publication":"2023 Feb","modification":"2025-04-21T19:49:25.565Z","creation":"2025-04-05T17:45:58.604Z"},"accession":"S-EPMC9986646","cross_references":{"pubmed":["36737039"],"doi":["10.1016/j.jlr.2023.100340"]}}